FLG and Alzheimer disease: As barrier integrity in AD varies due to factors such as filaggrin mutations, inflammation, and regional skin differences, tailoring drug vehicles using non-invasive measures like TEWL or lipid profiling may enhance therapeutic precision and reduce irritation [14].